EXHIBIT 99.1
| Press Release |  |
| www.shire.com |
Director Share Dealings
September 30, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that today Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, have been acquired for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from July 1 to September 30, 2014.
Type of Security (1) | Number of Shares/ADSs | ||
| Dominic Blakemore | Shares | 98 | |
| William Burns | Shares | 99 | |
| Dr. Steven Gillis | ADSs | 32 | |
| Dr. David Ginsburg | ADSs | 30 | |
| David Kappler | Shares | 104 | |
| Susan Kilsby | ADSs | 100 | |
| Anne Minto | Shares | 104 | |
| David Stout | ADSs | 32 | |
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at prices of £53.45 per Share and $259.9747 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
| Investor Relations | ||
| Jeff Poulton | jpoulton@shire.com | +1 781 482 0945 |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
| Media | ||
| Stephanie Fagan | sfagan@shire.com | +1 781 482 0460 |
| Gwen Fisher | gfisher@shire.com | +1 484 595 9836 |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com